Treatment-emergent sexual dysfunction with SSRIs and duloxetine: Effectiveness and functional outcomes over a 6-month observational period

International Journal of Psychiatry in Clinical Practice

Volumn 15, Issue 4, 2011, Pages 242-254

  Dueas, Héctor ^a   Brnabic, Alan J M ^b   Lee, Arier ^b   Montejo, Angel L ^c   Prakash, Siva ^d   Casimiro Querubin, Ma Luz S ^e   Khaled, Mohamed ^f   Dossenbach, Martin ^g   Raskin, Joel ^g  

^a Eli Lilly Mexico   (Mexico)

^b ELI LILLY AUSTRALIA PTY LTD   (Australia)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d NMC Hospitals   (United Arab Emirates)

^e ATENEO DE MANILA UNIVERSITY   (Philippines)

^f Saudi German Hospital   (Saudi Arabia)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

Antidepressant effectiveness; Arizona Sexual Experience (ASEX) scale; Duloxetine; Selective serotonin reuptake inhibitor (SSRI); Treatment emergent sexual dysfunction (TESD)

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ANORGASMIA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; FEMALE; GASTROENTERITIS; HUMAN; HYPOMANIA; INGUINAL HERNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOTHERAPY; QUALITY OF LIFE; RATING SCALE; REMISSION; SCORING SYSTEM; SEXUAL DYSFUNCTION; TREATMENT EMERGENT SEXUAL DYSFUNCTION; TREATMENT OUTCOME; UNITED STATES;

ADRENERGIC UPTAKE INHIBITORS; ADULT; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; THIOPHENES;

EID: 80053968697     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2011.590209     Document Type: Article

References (43)

1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. J Am Med Assoc 1999;281 : 537-44. (Pubitemid 29081307)
2. Montgomery SA, Baldwin DS, Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J Affect Disord 2002;69 : 119-40. (Pubitemid 34722878)
3. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29 : 259-66.
4. Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord 1999;56 : 201-8. (Pubitemid 30058223)
5. Bonierbale M, Lancon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 2003;19 : 114-24. (Pubitemid 36548126)
6. Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F et al. Sexual functioning assessed in 4 double-blind placebo-and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005;66 : 686-92. (Pubitemid 40942413)
7. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19 : 67-85. (Pubitemid 29047334)
8. Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002;36 : 1577-89.
9. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000;61 : 276-81. (Pubitemid 30305369)
10. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62(Suppl 3) : 10-21. (Pubitemid 32164676)
11. Perlis RH, Laje G, Smoller JW, Fava M, Rush AJ, McMahon FJ. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology 2009;34 : 1819-28.
12. Laje G, Perlis RH, Rush AJ, McMahon FJ. Pharmacogenetics studies in STARED: strengths, limitations, and results. Psychiatr Serv 2009;60 : 1446-57.
13. Zajecka JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry 2000;61(Suppl 2) : 20-5. (Pubitemid 30131899)
14. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, et al. SSRI-induced sexual dysfunction: fl uoxetine, paroxetine, sertraline, and fl uvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23 : 176-94. (Pubitemid 27514710)
15. Derogatis LR. Sexual function and quality of life: endpoints and outcomes. J Gend Specif Med 2001;4 : 35-42. (Pubitemid 34023986)
16. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63 : 357-66. (Pubitemid 34456365)
17. Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007; 4 : 917-29. (Pubitemid 47082256)
18. Schweitzer I, Maguire K, Ng C. Sexual side-effects of contemporary antidepressants: review. Aust NZ J Psychiatry 2009;43 : 795-808.
19. Haberfellner EM. A review of the assessment of antidepressant-induced sexual dysfunction used in randomized, controlled clinical trials. Pharmacopsychiatry 2007;40 : 173-82. (Pubitemid 47535743)
20. Due ñ as H, Lee A, Brnabic AJM, Chung KF, Lai CH, Badr MG, et al. Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study. Int J Psychiatry Clin Pract 2010;15:80-90.
21. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26 : 25-40. (Pubitemid 30046590)
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text Revision (DSM-IVTR); 2000.
23. World Health Organization (WHO). International classifi cation of diseases (ICD-10). Arlington, VA: American Psychiatric Publishing, Inc; 1992.
24. Guy W. ECDEU assessment manual for psychopharmacology-revised edition (DHEW Publ No ADM 76-338). Rockville, MD: NIMH Psychopharmacology Research Branch; 1976.
25. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54 : 573-83. (Pubitemid 37289444)
26. Due ñ as H, Tapia-Paniagua G, Vazquez-Barquero JL, Acuna A, Madrigal E, Celis A, et al. The integral inventory for depression (IID), a new clinimetric tool for the emotional and physically painful dimension of depression. Poster presented at the 2nd International Congress of the World Federation of Societies of Biological Psychiatry: 17-21 April 2007, Santiago, Chile.
27. EuroQol group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16 : 199-208.
28. Sheehan DV. The anxiety disease. New York: Charles Scribner & Sons; 1983.
29. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70 : 41-55.
30. D'Agostino RB Jr. Tutorial in biostatistics: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17 : 2265-81. (Pubitemid 28466823)
31. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004; 65 : 521-30.
32. Montejo AL, Prieto N, Terleira A, Matias J, Alonso S, Paniagua G, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol 2010; 24:111-20.
33. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ. Effi cacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007;27 : 672-6. (Pubitemid 351339455)
34. Jain R. The implications of pain and physical symptoms in depression. J Clin Psychiatry 2009;70 : e19.
35. Chalon SA, Granier LA, Vandenhende FR, Bieck PR, Bymaster FP, Joliat MJ, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a doubleblind, controlled study. Neuropsychopharmacology 2003; 28 : 1685-93. (Pubitemid 41070869)
36. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Effi cacy of duloxetine, a potent and balanced serotoninnorepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004;311 : 576-84. (Pubitemid 39391542)
37. Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004; 45 : 17-28. (Pubitemid 38082504)
38. Russell JM, Weisberg R, Fava M, Hartford JT, Erickson JS, D'Souza DN. Effi cacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically signifi cant pain symptoms. Depress Anxiety 2008;25 : E1-11.
39. Goldstein DJ. Duloxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2007;3 : 193-209. (Pubitemid 46864059)
40. Mu ñ oz RA, McBride ME, Brnabic AJ, Ló p ez CJ, Hetem LA, Secin R, et al. Major depressive disorder in Latin America: the relationship between depression severity, painful somatic symptoms, and quality of life. J Affect Disord 2005;86 : 93-8. (Pubitemid 40487965)
41. Chen KC, Yang YK, Lee IH, Yeh TL, Lu RB, Chen PS. Sexual dysfunction and physicians ' perception in medicated patients with major depression in Taiwan. Depress Anxiety 2008;25 : E56-62.
42. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006; 67(Suppl 6) : 33-7. (Pubitemid 44078111)
43. Hirschfeld RM. Management of sexual side effects of antidepressant therapy. J Clin Psychiatry 1999;60(Suppl 14):27-30. (Pubitemid 29343151)